Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

HIV Clinical Trials - Global Strategic Business Report 2026-2032 Featuring Strategic Intelligence on Gilead, ViiV Healthcare, Merck, and Pfizer

globenewswire.com

HIV Clinical Trials - Global Strategic Business Report 2026-2032 Featuring Strategic Intelligence on Gilead, ViiV Healthcare, Merck, and Pfizer Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "HIV Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global HIV clinical trials market was valued at US$1.5 billion in 2025 and is projected to reach US$2.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 4.8%. Market growth is supported by sustained investment in HIV research, increased development of long-acting antiretroviral therapies, expanding vaccine pipelines, and the adoption of advanced technologies across clinical research.

Key HIV Clinical Trials Market Trends and Growth Drivers

Researchers are advancing long-acting antiretrovirals, functional cure strategies, preventive vaccines, combination therapies, and antibody-based treatments. Pharmaceutical and biopharmaceutical companies, governments, academic institutions, and nonprofit organizations are investing in treatment regimens designed to improve adherence, strengthen viral suppression, address drug resistance, and reduce adverse effects.

Injectable and implantable antiretroviral therapies are reshaping clinical development by offering alternatives to daily oral medication. Pre-exposure prophylaxis, broadly neutralizing antibodies, nanomedicine, and personalized treatment strategies are also gaining prominence as clinical programs pursue more durable and targeted approaches to HIV treatment and prevention.

Technology Innovation in HIV Clinical Research

Artificial intelligence, genomic sequencing, CRISPR-based gene editing, digital health platforms, and predictive analytics are transforming HIV clinical trial design and execution. Artificial intelligence supports patient recruitment, biomarker identification, protocol optimization, and predictive modeling. Gene-editing research is investigating long-term viral suppression and the potential elimination of persistent HIV reservoirs.

mRNA vaccine platforms have also created new opportunities for preventive HIV vaccine research. Meanwhile, decentralized and virtual clinical trial models-including telemedicine, remote monitoring, and digital patient engagement-are improving recruitment, participation, and retention. These models are particularly relevant in low-resource settings and regions with high HIV incidence.

Government Initiatives and Global Collaboration

Public-private partnerships and funding from organizations such as UNAIDS, the National Institutes of Health, the Gates Foundation, and the World Health Organization continue to accelerate HIV clinical research. Regulatory fast-track mechanisms are supporting the evaluation of promising therapies, while diversity initiatives are encouraging broader representation across ethnic, demographic, and geographic populations.

Market Segment and Regional Outlook

Report Scope

The report analyzes the global HIV clinical trials market by value and provides forecasts from 2025 through 2032. Market segmentation includes:

Strategic Value of the Report

Companies Featured

Companies and organizations covered include AbbVie Inc.; AIDS Clinical Trials Group; AstraZeneca plc; Bristol-Myers Squibb Company; Charles River Laboratories International, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline plc through ViiV Healthcare; HIV Vaccine Trials Network; ICON plc; IQVIA Holdings Inc.; Janssen Pharmaceutical Companies; Merck & Co., Inc.; Parexel International Corporation; Pfizer Inc.; PPD, Inc.; Roche Holding AG; Sanofi S.A.; SGS SA; Syneos Health; and WuXi AppTec.

Domain Expert Insights

The report tracks early market signals emerging from expert discussions, company activity, scientific conferences, keynotes, panel sessions, corporate disclosures, annual reports, institutional publications, and other validated intelligence sources. These perspectives provide additional context for assessing technological progress, competitive positioning, regional market structures, and strategic direction.

Competitive analysis extends beyond a single global market share estimate. Where analytically relevant, the report evaluates market share across major regions to reflect differences in local trial infrastructure, sponsor participation, regulatory conditions, research funding, and therapeutic pipelines. This approach connects emerging signals with the developments most likely to influence the future of the global HIV clinical trials market.

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/6vbfxz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.